Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has been awarded a $4 million NIH grant to fund research on its pioneering intranasal anti-CD3 monoclonal antibody foralumab as a potential treatment for Alzheimer’s disease. The grant will accelerate the company’s research efforts, including preclinical studies and preparations for clinical trials targeting immune system modulation to slow the disease’s progression. Tiziana is advancing its development pipeline with this support, highlighting its commitment to addressing the urgent need for new therapeutic options in neurodegenerative diseases.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
